COMPANY

Gigamune, Inc.

HQ: San Francisco, CA source · gigamune.com ↗ · West Coast

Location: San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

8NIH grants

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 4R44CA310160-02, extension, notice Sep 9, 2026). NIH RePORTER 4R44CA310160-02 (Sep 9, 2026)
Evidence (1 event)
- Sep 9, 2026 · NIH RePORTER 4R44CA310160-02
  Organization: GIGAMUNE, INC.; City/State: SAN FRANCISCO, CA; Project number: 4R44CA310160-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-09; FY total cost (award amount): 1000000; Administering IC: National Cancer Institute; Project title: A Novel Lentivector for Enhanced In Vivo Delivery of T Cell Receptors for Cell Therapy for Stage IV Melanoma; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 9, 2026 Grant Government grant — SBIR: $1M (annual award, as published), announced Sep 9, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 12, 2025 Grant Government grant — SBIR: $400,000 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Funding

Last 2 years.

Sep 9, 2026 Government grant — SBIR: $1M (annual award, as published), announced Sep 9, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 12, 2025 Government grant — SBIR: $400,000 (annual award, as published), announced Sep 12, 2025. Agency: NIH/NCI. Source: government award database. source ↗

NIH awards 8

Annual award amounts. Total $2.4M.

Sep 5, 2024 NIH award 1R43HL174204-01A1 FY2024: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI JOHNSON, DAVID SCOTT; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. In vivo Sickle Cell Disease Gene Thera source ↗
Aug 22, 2023 NIH award 1R43AR082726-01 FY2023: $295,294 awarded for that fiscal year; activity R43 (SBIR); PI JOHNSON, DAVID SCOTT; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Delivery of Full Length Dystrophin to Mu source ↗
May 3, 2023 NIH award 3R43AI170407-01A1S1 FY2023: $55,000 awarded for that fiscal year; activity R43 (SBIR); PI SPINDLER, MATTHEW JAMES; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Engineered TCR-Treg Cell Therapies source ↗
Apr 19, 2023 NIH award 1R43AI179244-01 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI JOHNSON, DAVID SCOTT; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. In vivo Gene Delivery to Regulatory T Ce source ↗
Aug 11, 2022 NIH award 1R43AI170407-01A1 FY2022: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI SPINDLER, MATTHEW JAMES; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Engineered TCR-Treg Cell Therapies source ↗
Jul 22, 2021 NIH award 1R43CA265475-01 FY2021: $400,000 awarded for that fiscal year; activity R43 (SBIR); PI SPINDLER, MATTHEW JAMES; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Engineered TCR-T Cell Therapies Targe source ↗
Apr 28, 2021 NIH award 1R43CA257260-01A1 FY2021: $400,000 awarded for that fiscal year; activity R43 (SBIR); PI SPINDLER, MATTHEW JAMES; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Engineered TCR-T Cell Therapy Targe source ↗
Sep 5, 2018 NIH award 1R43CA232942-01 FY2018: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI SPINDLER, MATTHEW JAMES; recipient as written: GIGAMUNE, INC., SAN FRANCISCO, CA. Recombinant TIL Cell Therapy for Salv source ↗